Telomir Pharmaceuticals (NASDAQ: TELO) has announced the peer-reviewed publication of preclinical data for its lead candidate, Telomir-Zn, demonstrating its potential to treat triple-negative breast cancer (TNBC) and prostate cancer. The findings, published in the Journal of Oncology Research and Therapy, reveal that Telomir-Zn suppresses tumor growth by selectively modulating intracellular iron and copper levels, offering a novel approach to cancer therapy.
The study highlights Telomir-Zn's mechanism of action, which involves inhibiting histone demethylases through the depletion of intracellular iron. This process selectively kills iron-dependent TNBC cells while sparing normal cells, even at concentrations more than 50-fold higher than those affecting cancer cells. Additionally, the compound reactivated tumor-suppressor genes in a prostate cancer model, indicating broad epigenetic and metabolic effects.
In TNBC xenograft models, Telomir-Zn reduced primary tumor size across several cell lines and significantly decreased metastatic dissemination in HCC1806 xenografts. Notably, combining Telomir-Zn with paclitaxel in BT-549 xenografts produced a greater tumor reduction than either treatment alone, suggesting potential for combination therapy. However, MDA-MB-231 xenografts did not respond, underscoring tumor-specific differences in sensitivity that could inform patient selection in future trials.
These findings provide the scientific foundation for advancing Telomir-Zn into a planned Phase 1/2 clinical trial in TNBC under the company's active Investigational New Drug (IND) application. Telomir Pharmaceuticals is a clinical-stage biotechnology company focused on developing small-molecule therapeutics that target epigenetic and metabolic pathways implicated in cancer. The company's lead program, Telomir-Zn, has received IND clearance from the U.S. Food and Drug Administration for a Phase 1/2 trial in patients with advanced or metastatic TNBC.
The publication of this data marks a significant milestone for Telomir Pharmaceuticals, as it validates the preclinical rationale for Telomir-Zn and supports its continued development. The potential of Telomir-Zn to address TNBC, a particularly aggressive and difficult-to-treat cancer, is of great interest to the oncology community. With limited treatment options for TNBC, novel therapies that target fundamental cellular processes like metal homeostasis could offer new hope for patients.
For more information on the full press release, visit https://ibn.fm/mv3hn. The latest news and updates on Telomir Pharmaceuticals are available in the company's newsroom at https://ibn.fm/TELO.
